CCND1 and non-small cell lung carcinoma: In addition, downregulating CCND1 expression is beneficial to enhance the toxicity and sensitivity of some chemotherapeutic drugs (5-FU, gefitinib, cisplatin) to drug-resistant NSCLC (40).